ANTXAN2 Therapeutics, Inc.同业对比
AN2 Therapeutics, Inc. 与SIC 2834 行业的逐项对比:市值、估值、增长、盈利能力、质量与总回报,以及在同业组内的排名。所有数值均由引擎从 SEC 申报与延迟行情计算,排名仅为组内排序位置 —— 描述性数据,非投资建议。
完整同业对比
同业组:同 SIC 行业分类 | 公司 | 市值 | 市盈率(TTM) | 市净率 | 市销率 | 营收同比增长 | 净利同比增长 | 息税前利润率 | 净资产收益率 | 投入资本回报率 | 皮氏 F 值 | 一年总回报 | 股息率 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ANTX本股 | $170M#11 | — | 2.1x#5 | — | — | 31.5%#4 | — | -43.0%#5 | — | — | 337.0%#1 | — |
| AAPG | $7.1B#4 | — | — | — | — | — | — | — | — | — | -52.5%#14 | — |
| AARD | $141M#12 | — | 1.6x#3 | — | — | -179.7%#11 | — | -66.2%#8 | — | — | -50.1%#13 | — |
| ABBV | $464.9B#1 | 129.6x#5 | — | 7.6x#3 | 8.6%#5 | -1.2%#8 | 24.6%#1 | — | 20.0%#1 | — | 41.0%#4 | 2.5%#1 |
| ABCL | $1.6B#6 | — | 1.7x#4 | 21.5x#4 | 160.6%#1 | 10.1%#5 | -289.0%#5 | -15.6%#4 | -25.2%#4 | — | 12.9%#8 | — |
| ABEO | $344M#9 | 6.3x#2 | 2.4x#6 | 59.1x#5 | — | -211.7%#12 | -1536.9%#7 | -49.1%#7 | -101.1%#7 | — | -10.7%#10 | — |
| ABT | $186.9B#2 | 30.1x#4 | 3.6x#10 | 4.2x#2 | 5.7%#6 | -51.3%#9 | 18.2%#2 | 12.5%#2 | 8.3%#3 | — | -14.4%#11 | 2.2%#2 |
| ABUS | $873M#7 | 5.3x#1 | 3.4x#8 | 62.0x#6 | 128.2%#2 | 52.1%#2 | -271.0%#4 | -12.9%#3 | — | — | 33.5%#5 | — |
| ABVC | $28M#15 | — | 2.6x#7 | 93.5x#7 | 48.0%#3 | -61.3%#10 | -2416.0%#8 | -73.4%#9 | -65.9%#6 | — | -64.1%#15 | — |
| ABVX | $9.8B#3 | — | — | — | — | — | — | — | — | — | 77.4%#3 | — |
| ACAD | $4.5B#5 | 11.8x#3 | 3.6x#9 | 4.2x#1 | 11.9%#4 | 73.0%#1 | 9.8%#3 | 31.3%#1 | 10.9%#2 | — | 14.9%#7 | — |
| ACET | $78M#13 | — | 0.6x#1 | — | — | 0.3%#7 | — | -83.4%#11 | — | — | -25.6%#12 | — |
| ACIU | $235M#10 | — | — | — | — | — | — | — | — | — | 0.9%#9 | — |
| ACRS | $744M#8 | — | 5.2x#11 | 95.1x#8 | -58.2%#7 | 50.8%#3 | -975.9%#6 | -45.2%#6 | -60.8%#5 | 3#1 | 242.8%#2 | — |
| ACRV | $66M#14 | — | 0.7x#2 | — | — | 3.3%#6 | — | -81.6%#10 | — | — | 15.8%#6 | — |
数值来自 SEC 申报与延迟行情;排名仅为该组内的排序位置 —— 描述性数据,不构成评级或建议。 本表构建超时,仅覆盖该组的一部分成员;排名仅相对于已列出的行,稍后会自动补全。 数据构建于 2026-07-29。
数据来自 SEC XBRL 申报与延迟行情 · 排名为组内排序 · 仅供参考 · 非投资建议